Prescription Drugs

  • |

    Public Science, Private Checkout

    ByHarlan Quill

    I keep a library card and a calculator nearby for moments like this: taxpayers help fund NIH and university research, then meet the finished medicine at the pharmacy counter priced like a used county courthouse. Not every treatment follows that exact route, and public research can benefit everyone. But when public money absorbs much of the early risk while private companies control the patent and the price, the arrangement deserves more than a ceremonial ribbon cutting.

    The institutional math is remarkably tidy. Public laboratories supply knowledge, universities supply talent, investors celebrate the next big product, and patients receive the portion marked “due now.” That is not necessarily unlawful; it is simply a system with impressive machinery for privatizing the upside and outsourcing the bill. A sensible public investment should purchase public leverage, affordable access, or both. Otherwise taxpayers sponsored discovery, investors collected the dividend, and patients were assigned to crowd-fund the receipt.

  • |

    Medicare’s Taxpayer-Funded Layaway Plan

    ByHarlan Quill

    At the courthouse-basement level of policy math, the arrangement is hard to defend: taxpayers help absorb the early risk of medical discovery, then a private patent can put the finished medicine behind a padlock while Medicare and patients meet the checkout price.

    That is a taxpayer-funded layaway plan. We help finance the scientific groundwork, a company controls the bottle, and the public returns to retrieve its medicine with a bill wearing a shareholder-return hat. If public support helps make a breakthrough possible, public policy should at least ask what public value comes back. Otherwise, we did not merely buy the breakthrough; we rented it back from the company that put a padlock on the bottle.

  • |

    If Prices Can Fall Now, Who Approved the Old Ones?

    ByHarlan Quill

    I have spent enough time with budgets to know that when a Medicare drug price falls after negotiation, the old price deserves an audit—not a standing ovation. The usual sales pitch says Medicare must accept whatever number arrives in the envelope, as though drug pricing were a weather event and not a market with lawyers. Then bargaining happens, the bill gets smaller, and “impossible” suddenly develops a discount code.

    The exact before-and-after figures may be illustrative, and lower prices do not automatically shrink every patient’s copay. But the practical point survives the fine print: negotiation can reduce public spending and may ease the bill at the pharmacy counter. The people defending the old system now have to explain why savings were forbidden until someone asked for them. The national drug-pricing spreadsheet has ruled that “unavoidable” was apparently the premium tier, complete with a lobbyist and no cancellation button.

End of content

End of content